Navigation Links
New imaging agent enables better cancer detection, more accurate staging
Date:3/20/2013

Researchers at the University of California, San Diego School of Medicine have shown that a new imaging dye, designed and developed at UC San Diego Moores Cancer Center, is an effective agent in detecting and mapping cancers that have reached the lymph nodes. The radioactive dye called Technetium Tc-99m tilmanocept, successfully identified cancerous lymph nodes and did a better job of marking cancers than the current standard dye. Results of the Phase III clinical trial published online today in the Annals of Surgical Oncology.

"Tilmanocept is a novel engineered radiopharmaceutical specifically designed for sentinel lymph node detection," said David R. Vera, PhD, the drug's inventor, who is a professor in the UCSD Department of Radiology. "The molecule, developed at UC San Diego School of Medicine, offers surgeons a new tool to accurately detect and stage melanoma and breast cancers while in the operating room."

On March 13, 2013, tilmanocept received U.S. Food and Drug Administration (FDA) approval.

After a cancer diagnosis, surgeons want to be sure that the disease has not spread to a patient's lymph nodes, especially the sentinel nodes that may be the first place that a cancer reaches. The lymphatic system is a network of vessels and ducts that carry disease-fighting cells throughout the body, but can also act as a way for cancer cells to access the bloodstream. By surgically removing and examining the sentinel nodes that drain a tumor, doctors can better determine if a cancer has spread.

"Tilmanocept advances the molecular targeting in breast cancer. It's the first agent that is binding to a lymph node because it is a lymph node that plays an important role in metastasis," said Anne Wallace, MD, professor of surgery, UC San Diego School of Medicine and principal investigator of the study. "Tilmanocept's ability to identify more cancer containing nodes will lead to better post-operative care for patients, especially those patients who had more than one positive sentinel node."

Doctors compared injections of tilmanocept, also called Lymphoseek, and the standard blue dye into the tumor area. Then, using a handheld radiation detector, they found the lymph nodes that had taken up the drugs radioactivity. The researchers found that more than 99 percent of sentinel lymph nodes containing blue dye also contained tilmanocept. Of these nodes, 18 percent were positive for cancer. Ninety-four percent of the malignancies were detected by the new radiopharmaceutical whereas the blue dye only detected 76 percent.

"Tilmanocept is just as accurate as current techniques, simple to use, takes less time to find lymph nodes and is cleared faster from the body. This could standardize the process of lymph node mapping and make the process easier, particularly for less experienced surgeons," said Wallace, chief of plastic surgery at UC San Diego Health System and director of the Breast Care Unit at UC San Diego Moores Cancer Center.

Tilmanocept was originally developed at UC San Diego by Vera. Wallace advanced the agent through Phase 1 clinical trials with funding provided by the Susan G. Komen Breast Cancer Foundation and the American Cancer Society. The Phase III study was supported by Navidea Biopharmaceuticals, Inc. based in Dublin, Ohio.

Lymphoseek's safety and effectiveness were established in two clinical trials of 332 patients with melanoma or breast cancer. The Phase III clinical trial took place at 13 medical centers involving 148 patients who had both melanoma and breast cancer. The most common side effects identified in clinical trials was pain or irritation at the injection site reported by two patients.


'/>"/>

Contact: Jackie Carr
jcarr@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. Revolutionary imaging software offers more detailed, clearer scans of heart conditions
2. Research and Markets announces the addition of the "Optical Imaging Market (2013-2018) - Technology Trends And Applications" Report to their Offering
3. Brain Imaging Detects Tiny Lesions Related to Mild Injury: Study
4. Illuminating fractures: X-ray imaging sheds new light on bone damage
5. Einstein researchers present on imaging advances
6. DAI provides potential imaging biomarker to indicate brain tumor response to RT
7. Imaging acute ischemic stroke patients brains did not lead to improved outcomes
8. Amyloid imaging shows promise for detecting cardiac amyloidosis
9. Breast Imaging (Breast MRI) Market is Growing at an Estimated CAGR of 15.37% & to Reach $5 Billion by 2017 - by MarketsandMarkets
10. First guidelines for brain amyloid imaging in Alzheimers released
11. Study: Transparent pricing doesnt curb doctors use of high-cost hospital imaging tests
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New imaging agent enables better cancer detection, more accurate staging
(Date:12/7/2016)... ... December 07, 2016 , ... A quote from Dr. Edward ... comments on social media that offer a rare glimpse into the mind of those ... and New York Times bestselling author, has described people with ADHD as having “Ferrari ...
(Date:12/7/2016)... Hollywood, Fl (PRWEB) , ... December 07, 2016 , ... When it came time to ... new heart. Just 40 minutes later, the Pediatric Heart Transplant team at Joe ... true making the Weston teen the hospital’s 30th heart transplant recipient. , “He was ...
(Date:12/7/2016)... ... 07, 2016 , ... Baciocco Brothers Insurance Agency, a northern ... Sacramento/Folsom region, is initiating a charity event to raise support and awareness for ... treatment center in Sacramento works to provide area teens and families with treatment ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving ... are not fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. ... to the children of the world. , In exchange for generous donations, customers will ...
(Date:12/7/2016)... ... 2016 , ... Sharon Kleyne, host of the nationally syndicated radio program, The ... of America, declared on her radio program in November 2016 the need to educate ... bullies attack leaders in corporate America, they are trying to take advantage of successful ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , December 7, 2016 ... Market Research titled , Global Market Study on Multiplex Detection ... 2024 , the global multiplex detection immunoassay market is expected ... period 2016-2024. ... , , ...
(Date:12/7/2016)... FRANCISCO , December 7, 2016 ... expected to reach a value of USD 3.9 ... by Grand View Research, Inc. The growth of ... of donor and continuous technological advancements by the ... increasing continuously due to increasing donation, rising awareness ...
(Date:12/6/2016)... , Dec. 6, 2016  Alopexx Oncology, LLC announced ... recombinant antibody fusion protein (immunocytokine) composed of interleukin-2 and ... same target on B cells as Rituxan and maintains ... but is also involved in tumor targeting, engagement of ... effect. The results of the study (abstract #95954) were ...
Breaking Medicine Technology: